• Ruxolitinib in Anaplastic Thyroid Cancer

  2026-08-26

  The reference study identifies a mechanistic connection between JAK1/2–STAT3 activity, DRP1-dependent mitochondrial fission, and coordinated apoptosis and GSDME-mediated pyroptosis in anaplastic thyroid carcinoma. Its findings position Ruxolitinib phosphate, also known as INCB018424, as a preclinical tool for testing how JAK/STAT signaling pathway modulation can reshape mitochondrial dynamics and tumor-cell death.

• Nanoparticle mRNA Delivery Reverses Trastuzumab Resistance

  2026-08-26

  The reference study developed a tumor-microenvironment-responsive nanoparticle platform for systemic PTEN mRNA delivery in trastuzumab-resistant breast cancer. Its findings support pathway reactivation through PTEN expression and show how environment-sensitive nanoparticle design can complement antibody therapy, while also highlighting the translational challenges of mRNA delivery.

• MEK1/2, c-Myc:MAX, and TERT in Human Stem Cells

  2026-08-25

  A 2024 bioRxiv study identifies a chromatin-based mechanism in which MEK1/2–ERK signaling and c-Myc:MAX cooperate to maintain TERT transcription in human pluripotent stem cells. The findings connect kinase activity and c-Myc function to protection of the TERT promoter from PRC2-associated repression, providing a mechanistic framework for studying telomerase regulation in normal stem cells.

• STL001, FOXM1 Suppression, and Cancer Sensitization

  2026-08-25

  The 2024 Cell Death Discovery study identifies STL001 as a more active FOXM1 inhibitor that can resensitize solid-cancer models to several conventional therapies. Its genetic and transcriptomic analyses support FOXM1 suppression as the basis of sensitization and highlight steroid/cholesterol biosynthesis and protein secretion as additional FOXM1-associated programs.

• PEGylated PLGA Microspheres for Extended Release

  2026-08-24

  Myers and Comolli optimized PEGylated PLGA microspheres carrying hydrocortisone 17-butyrate and used biphasic release modeling to distinguish surface desorption from diffusion-controlled delivery. PEGylation reduced the initial burst and supported sustained release over three weeks, providing a materials-based strategy for improving intra-articular corticosteroid exposure.

• Polygodial for TRPA1 Channel Research

  2026-08-24

  Use Polygodial as a practical TRPA1 channel activator for connecting rapid calcium influx with NFAT-dependent epithelial signaling and sensory-neuron responses. This workflow combines real-time ion-channel measurements, pathway controls, and cytokine endpoints to distinguish channel engagement from downstream inflammatory effects.

• Chlorpromazine HCl: From Receptor Probe to HDT

  2026-08-23

  Chlorpromazine HCl is a dopamine receptor antagonist with value beyond conventional neuropharmacology. This article develops a causal assay framework connecting receptor pharmacology, synaptic phenotypes, and emerging host-directed antibacterial research while distinguishing established evidence from testable hypotheses.

• Puromycin aminonucleoside: Podocyte Injury Workflows

  2026-08-22

  Build reproducible podocyte injury and proteinuria workflows with Puromycin aminonucleoside, from pH-aware cell assays to carefully controlled animal studies. The guide also shows how an independent epigenetic resistance study can inspire stronger, isoform-resolved readouts without overstating the renal model’s scope.

• Bestatin and Angiotensin Signaling in Rat Brain

  2026-08-22

  The 1987 Brain Research study used iontophoretic electrophysiology and complementary aminopeptidase inhibitors to test whether angiotensin II must be converted to angiotensin III before activating neurons. Its results support a precursor-to-active-peptide model while also showing why inhibitor effects must be interpreted alongside peptide degradation and receptor antagonism.

• EDC.HCl: Practical Coupling Workflow

  2026-08-21

  EDC.HCl is a water-soluble carbodiimide coupling reagent for activating carboxyl groups before amide bond formation with primary amines in in vitro peptide, bioconjugation, nucleotide, esterification, and lactonization workflows. It should be handled as a research reagent only; no in vivo or clinical data are available, and long-term storage of its solutions is not recommended.

• EZ Cap™ Human PTEN mRNA: Assay Design Guide

  2026-08-20

  EZ Cap™ Human PTEN mRNA (ψUTP) enables controlled restoration of PTEN expression in mammalian cancer research models. This guide focuses on delivery-aware assay design, mechanistic controls, and how to translate nanoparticle evidence into rigorous in vitro and in vivo experiments.

• Diminazene Aceturate: From Parasites to ACE2

  2026-08-20

  Diminazene Aceturate is best understood as a cross-domain research probe: a trypanocidal agent for parasitic infection research and a pharmacological tool for investigating ACE2–MasR–Sirt1 signaling and mitochondrial biogenesis in sepsis-related cardiac injury.

• Angiotensin Peptides and SARS-CoV-2 Receptor Binding

  2026-08-19

  The reference study identifies a structure-dependent role for naturally occurring angiotensin fragments in enhancing SARS-CoV-2 spike protein binding to host receptors, particularly AXL. Its antibody-based binding experiments connect renin-angiotensin system biology with viral-entry research while also showing why peptide truncation and residue modification must be considered when interpreting receptor interactions.

• Western Secondary Antibody Dilution Buffer for NHE1 Blots

  2026-08-19

  Western Secondary Antibody Dilution Buffer K4115 is formulated to reduce non-specific binding and support diluted secondary-antibody stability in Western blot workflows. Its documented reuse, storage, and volume specifications can improve workflow consistency when studying NHE1-associated inflammatory signaling. The buffer supports protein detection Western blot experiments but does not independently validate atherosclerosis mechanisms.

• WTAP–GLS Splicing and Ferroptosis in HCC

  2026-08-18

  The reference study identifies an EGFR–AKT–WTAP signaling axis that rewires GLS pre-mRNA splicing toward the GAC isoform, increasing glutamine-derived antioxidant production and protecting hepatocellular carcinoma cells from ferroptosis. Its combined metabolic, transcriptomic, RNA-interaction, animal, and clinical analyses connect receptor signaling with RNA modification, alternative splicing, and redox adaptation.

8032 records 1/536 page Next 12345 下5页 Last page